Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168727 · ClinicalTrials.gov registry record · Phase 4
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma
A Phase 4 study of Lymphoma, Non-Hodgkin and Lymphoma, Low-Grade, sponsored by Biogen.
- Completed
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 8
- Study locations
NCT00168727: Completed Phase 4 study of Lymphoma, Non-Hodgkin and Lymphoma, Low-Grade, sponsored by Biogen.
NCT00168727 is a Phase 4 study of Lymphoma, Non-Hodgkin and Lymphoma, Low-Grade that has completed, run by Biogen. The registered enrollment target is 12 participants, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00168727, a Phase 4 study of Lymphoma, Non-Hodgkin and Lymphoma, Low-Grade, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have been previously treated. This study will use an experimental scheduling regimen. No chemotherapy will be used in this study.
Conditions Studied
Interventions
- DRUG ibritumomab tiuxetan (Zevalin®)
Study Locations (8)
California
- Loma Linda University - Loma Linda
- North County Oncology - Oceanside
Connecticut
- Medical Specialists of Fairfield - Fairfield
Hawaii
- Queens Hospital - Honolulu
Illinois
- Northwest Oncology and Hematology - Elk Grove Village
Indiana
- Horizon Oncolgy Center - Lafayette
Missouri
- Specialists in Hematology/Oncology - St Louis
North Carolina
- Presbyterian Hospital Cancer Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2003-06-01 |
| Est. Completion | 2005-10-31 |
| Phase | Phase 4 |
What the finished NCT00168727 record still lists
NCT00168727 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 389-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 1 intervention - of which ibritumomab tiuxetan (Zevalin®) is the first listed.
NCT00168727 lists 8 locations in 7 states (California, Connecticut, Hawaii).
Frequently Asked Questions
What is clinical trial NCT00168727 about?
NCT00168727 is a clinical study titled "Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma". The purpose of this study is to determine the safety and effectiveness of a treatment regimen using Zevalin® plus Rituxan® for patients who have low grade Non-Hodgkin's Lymphoma (NHL) or relapsed Non-Hodgkin's lymphoma and have been previously treated. This study will use an experimental scheduling ...
What is the current status of trial NCT00168727?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2003-06-01. Estimated completion is 2005-10-31.
What conditions does trial NCT00168727 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade.
What interventions are being tested in trial NCT00168727?
The interventions under investigation include: ibritumomab tiuxetan (Zevalin®) (DRUG).
Who is sponsoring clinical trial NCT00168727?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00168727 being conducted?
This trial has 8 study locations across California, Connecticut, Hawaii, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00168727's enrollment target sits among peer trials
12 57th of 58 higher than 2 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
ACTIVE NOT RECRUITING · Phase 4
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease
RECRUITING
-
Family Study of Lymphoproliferative Disorders
RECRUITING
-
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI